Special Issue

Psychopharmacology and Biological Studies of Psychosis

Message from the Guest Editors

Psychotic disorders (including schizophrenia and schizophrenia-related disorders) cover a wide group of mental illnesses, with a total incidence rate estimated at approximately 4/1000/year. Due to the significant heterogeneity, research into the biological mechanisms of these disorders is a huge challenge, and we are far from understanding their detailed etiology and pathophysiology. While there is significant progress in the field of psychopharmacotherapy, still, only about half of patients with a diagnosis of schizophrenia achieve symptomatic remission, and only a quarter of them have adequate social functioning after a long period of treatment. In addition, approximately one-third of patients are drug-resistant. A significant problem in the pharmacotherapy of psychoses is their multidimensional nature (the need to simultaneously influence positive, negative, and affective symptoms, as well as cognitive and behavioral disorders), treatment nonadherence, side effects of antipsychotic drugs, somatic consequences of their use and general medical comorbidity. In this Special Issue, our aim will be to focus on the challenges of psychopharmacology and biological studies of psychosis.

Guest Editors

Dr. Marcin Siwek

Dr. Adrian Andrzej Chrobak

Dr. Bernadeta Szewczyk

Deadline for manuscript submissions

closed (5 February 2023)



Brain Sciences

an Open Access Journal by MDPI

Impact Factor 2.7
CiteScore 4.8
Indexed in PubMed



mdpi.com/si/130410

Brain Sciences MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 brainsci@mdpi.com

mdpi.com/journal/ brainsci





Brain Sci<u>ences</u>

an Open Access Journal by MDPI

Impact Factor 2.7 CiteScore 4.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

Editor-in-Chief

Prof. Dr. Stephen D. Meriney

Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260. USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYNDEX, PsycInfo, CAPlus / SciFinder, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 12.9 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.

